ProMIS Neurosciences earnings release, August 13, 2026

ProMIS Neurosciences Inc. (PMN) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Cambridge, Massachusetts, August 13, 2026 (GLOBE NEWSWIRE) --

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.

“The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while maintaining a strong financial position,” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “We ended the quarter with $53.4 million in cash and short-term investments, providing runway through 2027, beyond our next major anticipated catalyst.”

“Subsequent to quarter end, on July 28 th, we announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, our Phase 1b trial of PMN310 in patients with early AD. Across all 136 safety-evaluable participants and APOE genotypes, we observed no cases of ARIA-E. We also observed an early and directionally consistent movement in plasma pTau217 and CSF MTBR-tau243 in the blinded analysis, which pooled active and placebo-treated patients.”

“We believe these data reinforce the thesis behind PMN310: that selectively targeting toxic amyloid-beta oligomers and avoiding plaque may offer a path to amyloid-directed therapy with a significantly improved safety profile, including a substantially reduced ARIA burden, and a potential for improved efficacy. We look forward to the 12-month unblinded topline results from PRECISE-AD, expected in the first quarter of 2027, which will include cognitive outcomes, and we believe will represent an important next step in evaluating PMN310’s potential for patients with early AD.”

Corporate Highlights

Alzheimer’s Disease (AD) Program (PMN310) — PRECISE-AD Interim Data

Pipeline Progress and Scientific Presentations

Corporate and Investor Activities

Future Activities and Upcoming Milestones

Second Quarter 2026 Financial Highlights

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)

PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. Because PMN310 may not be limited by off-target binding or side effects, it could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.

PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD or mild AD (Stage 3 and Stage 4 AD). PRECISE-AD is the first study to examine the effects of a monoclonal antibody directed solely against Aβ oligomers on biomarkers associated with AD pathology and clinical outcomes. Safety is a primary outcome of the study, with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA and is designed to provide meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes.

EpiSelect™ Drug Discovery Engine

Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelect™) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations.

Financial statements

Income Statement

Three Months Ended June 30, 2026 — Condensed Consolidated Statements of Operations (Unaudited)

Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development9,521,7938,749,78416,492,79914,214,034
General and administrative2,744,6061,434,8774,418,4973,430,723
Total operating expenses12,266,39910,184,66120,911,29617,644,757
Loss from operations-12,266,399-10,184,661-20,911,296-17,644,757
Other income536,74367,632937,267179,825
Net loss-11,729,656-10,117,029-19,974,029-17,464,932
Net loss per share, basic and diluted-1.28-7.26-2.54-12.53
Weighted-average outstanding Common Shares, basic and diluted9,142,3661,394,0487,874,5621,394,048

Balance Sheet

June 30, 2026 — Condensed Consolidated Balance Sheets (Unaudited)

June 30, 2026December 31, 2025
AssetsCash53,429,2806,116,556
AssetsShort-term investments33,75333,753
AssetsPrepaid expenses and other current assets3,230,9003,032,112
AssetsTotal current assets56,693,9339,182,421
AssetsTotal assets56,693,9339,182,421
Liabilities and Shareholders’ EquityAccounts payable1,793,4752,543,415
Liabilities and Shareholders’ EquityAccrued liabilities5,424,2697,868,416
Liabilities and Shareholders’ EquityTotal current liabilities7,217,74410,411,831
Liabilities and Shareholders’ EquityShare-based compensation liability77,25529,182
Liabilities and Shareholders’ EquityTotal liabilities7,294,99910,441,013
Liabilities and Shareholders’ EquityAdditional paid-in capital200,150,367129,518,812
Liabilities and Shareholders’ EquityAccumulated other comprehensive loss-371,184-371,184
Liabilities and Shareholders’ EquityAccumulated deficit-150,380,249-130,406,220
Liabilities and Shareholders’ EquityTotal shareholders’ equity (deficit)49,398,934-1,258,592
Liabilities and Shareholders’ EquityTotal liabilities and shareholders’ equity (deficit)56,693,9339,182,421
Full release

Forward-Looking Statements... (truncated)217, and MTBR-tau243 findings) described in this release, the expected timing and nature of topline clinical data of PMN310, its mechanism of action and potential benefits, the potential for PMN310 to offer a differentiated efficacy and safety profile relative to plaque-directed antibodies; the Company’s belief that toxic soluble amyloid-beta oligomers are a primary driver of cognitive decline in AD; statements related to the Company’s preclinical programs; and the Company’s expectation that existing cash resources will fund planned operations through 2027. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates, and projections regarding the future of the business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions, and other factors that may cause actual results, level of activity, performance or achievement to differ materially from those expressed or implied, including, but not limited to, the risk that early or interim results may not be indicative of final or top-line results, the Company’s accumulated deficit, and the expectation for continued losses. Important factors that could cause actual results to differ materially are discussed in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and in its subsequent filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Condensed Consolidated Balance Sheets (Unaudited)

​

Condensed Consolidated Statements of Operations (Unaudited)

​

For Investor Relations, please contact:

Carie Pierce

VP, Investor Relations & External Affairs

IR@promisneurosciences.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.